



## CORRECTION



# Correction: Cancer-associated fibroblast senescence and its relation with tumour-infiltrating lymphocytes and PD-L1 expressions in intrahepatic cholangiocarcinoma

Chuan Lan , Yuki Kitano, Yo-ichi Yamashita, Takanobu Yamao, Kiyoshi Kajiyama, Tomoharu Yoshizumi, Kengo Fukuzawa, Keishi Sugimachi, Yasuharu Ikeda, Hiroshi Takamori, Nobutomo Miyanari, Masahiko Hirota and Hideo Baba 

© The Author(s), under exclusive licence to Springer Nature Limited 2021

*British Journal of Cancer* (2022) 126:311–312; <https://doi.org/10.1038/s41416-021-01615-3>

Correction to: *British Journal of Cancer* <https://doi.org/10.1038/s41416-021-01569-6>, published online 06 October 2021

The original version of this article unfortunately contained a mistake. There was a misalignment in Fig. 1. In addition, Table 1 is incorrect. The authors apologize for the oversight. The original article has been corrected.

**Table 1.** Clinicopathological features and CAV1 expression in CAFs.

	Total (n = 158)	CAV1 expression in CAFs		p value
		Negative (n = 80)	Positive (n = 78)	
Age (yr)	67.3 ± 10.3	65.8 ± 10.7	68.7 ± 9.7	0.080
Sex				0.434
Male	88 (55.7%)	47 (58.7%)	41 (52.6%)	
Female	70 (44.3%)	33 (41.3%)	37 (47.4%)	
BMI	22.8 ± 3.2	22.4 ± 3.3	23.2 ± 3.1	0.117
CEA (ng/mL)	3.0 (0.6–1692)	2.9 (0.6–1692)	3.1 (0.7–150.1)	0.123
CA19-9 (ng/mL)	36.0 (0–74,079)	22.8 (0.1–36,230)	54.1 (0–74,079)	0.001
PLT	19.8 (5.1–296)	19.6 (5.4–159)	20.7 (5.1–296)	0.953
Total bilirubin (mg/dL)	0.7 (0.1–13.4)	0.7 (0.1–1.6)	0.7 (0.2–13.4)	0.548
Albumin (g/dL)	4.1 (2.6–5.1)	4.1 (3.1–5.1)	4.1 (2.6–4.9)	0.615
Tumor size (mm)	39 (1–180)	35 (1–120)	40 (2.5–180)	0.337
pT				0.046
T0–2	109 (69.0%)	61 (76.3%)	48 (61.5%)	
T3, 4	49 (31.0%)	19 (23.7%)	30 (38.5%)	
pN				0.004
No	128 (81.0%)	72 (90.0%)	56 (71.8%)	
Yes	30 (19.0%)	8 (10.0%)	22 (28.2%)	
Operating time (min)	369.9 ± 131.6	385.7 ± 137.6	353.7 ± 123.8	0.126
Blood loss (mL)	467.5 (2–5140)	437.5 (5–2897)	560 (29–5140)	0.105
Differentiation				0.337
Well/Mod	107 (67.7%)	57 (71.3%)	50 (64.1%)	
Poor	51 (32.3%)	23 (28.7%)	28 (35.9%)	
Postoperative chemotherapy				0.523
No	117 (74.1%)	61 (76.3%)	56 (71.8%)	
Yes	41 (25.9%)	19 (23.7%)	22 (28.2%)	

CAV1 caveolin-1, CAFs cancer-associated fibroblasts, BMI body mass index, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9, pT pathological tumor stage, pN pathological nodal stage, Mod moderately, Poor poorly.